Compare Alcon AG (ALC) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Icl Group Ltd — how do they compare? Alcon AG trades at $74.32 (market cap $36.44B), while Icl Group Ltd trades at $5.3 (market cap $6.94B). The key difference: Alcon AG is far larger — about 5.3× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| ALC | ICL | |
|---|---|---|
Market Cap | $36.44B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $90.12 | $6.84 |
52-Week Low | $62.02 | $4.80 |
Enterprise Value | $40.28B | $9.58B |
Dividend Yield | 0.48% | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
ICL trades at $5.465, up 2.34% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, and revenue is projected to grow to $7.7B in 2026. Recent news highlights strong quarterly results and a senior notes offering. The stock shows a neutral sentiment from oscillators, while analyst consensus is entirely Hold.
The outlook is mixed; earnings beats and operational improvements support upside, but declining net margins and a unanimous Hold rating from analysts suggest limited near-term catalysts. Key risks include raw material cost pressures and foreign exchange volatility, which could impact profitability despite positive cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
